Zymeworks Stock News

SVB Leerink restated their hold rating on shares of Zymeworks (NYSE:ZYME) in a report published on Monday, Price Targets.com reports. They currently have a $43.00 price objective on the stock. SVB Leerink also issued estimates for Zymeworks FY2024 earnings at ($5.76) EPS and FY2025 earnings at ($4.32) EPS. ZYME has been the subject of a []

Zymeworks (NYSE:ZYME)s stock had its hold rating reiterated by stock analysts at SVB Leerink in a report issued on Monday, Analyst Ratings Network reports. They currently have a $43.00 target price on the stock. SVB Leerinks price objective indicates a potential upside of 116.19% from the companys current price. SVB Leerink also issued estimates for []

Related Stocks: YY , SLAM , ZYME , LIDR , EVGO , OUST , WB , WORK , ALXN , MXIM , GNW , PACE , SVAC ,

Northern Trust Corp boosted its position in Zymeworks Inc. (NYSE:ZYME) by 506.9% during the 2nd quarter, HoldingsChannel.com reports. The firm owned 246,207 shares of the companys stock after purchasing an additional 205,639 shares during the quarter. Northern Trust Corps holdings in Zymeworks were worth $8,541,000 at the end of the most recent reporting period. A []

Weiss Multi Strategy Advisers LLC lifted its stake in shares of Zymeworks Inc. (NYSE:ZYME) by 3.7% in the 2nd quarter, HoldingsChannel reports. The firm owned 17,077 shares of the companys stock after buying an additional 612 shares during the quarter. Weiss Multi Strategy Advisers LLCs holdings in Zymeworks were worth $592,000 as of its most []

VANCOUVER, British Columbia--(BUSINESS WIRE)--Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that management will p

Zymeworks Inc. (ZYME) delivered earnings and revenue surprises of -5.93% and -50.03%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

VANCOUVER, British Columbia--(BUSINESS WIRE)--Zymeworks Inc. (NYSE:ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that management will ho

Zymeworks (ZYME) has been struggling lately, but the selling pressure may be coming to an end soon.

Zymeworks Inc. (ZYME) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in rev

At the European Society of Medical Oncology Congress 2021 (ESMO21), Zymeworks Inc (NYSE: ZYME) presented encouraging early data on its HER2‑targeted bispecific antibody. Twenty-eight patients were d

VANCOUVER, British Columbia--(BUSINESS WIRE)--Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that new clinical data

VANCOUVER, British Columbia--(BUSINESS WIRE)--This press release announces the availability of an abstract that Zymeworks is presenting at the upcoming ESMO Congress

THS, ZYME, NTRA, LAWS, and INSW have been added to the Zacks Rank #5 (Strong Sell) List on August 10, 2021

Zymeworks Inc. (ZYME) delivered earnings and revenue surprises of -23.58% and -75.61%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?